IDEAYA Biosciences Signs Clinical Collaboration with Genentech for IDE892 in MTAP-Deleted PDAC

IDEAYA Biosciences will supply IDE892 into a Genentech-sponsored Phase 1 combination trial, a structural arrangement that places clinical supply chain accountability squarely on IDEAYA's QA and manufacturing teams while Genentech retains trial sponsorship. The collaboration targets pancreatic ductal adenocarcinoma harboring both an MTAP deletion and a KRAS G12D mutation, a co-occurring genomic profile estimated in up to 15% of PDAC patients with no currently approved targeted treatment options.

Under the agreement, IDEAYA will provide IDE892, its investigational MTA-cooperative PRMT5 inhibitor, for evaluation alongside GDC-7035 (RG6620), Genentech's Phase 1 KRAS G12D inhibitor. Joint governance will oversee the clinical supply collaboration, a mechanism that distributes oversight responsibility across both organizations and introduces cross-company quality agreements as a practical necessity. For QA directors managing investigational medicinal product release, the dual-sponsor model requires clear delineation of batch disposition authority and deviation escalation pathways before first patient dosing.

IDE892's pharmacological profile is directly relevant to combination feasibility assessments. The compound demonstrated a CYP3A4 IC50 greater than 45 micromolar and no time-dependent inhibition across all seven major cytochrome P450 enzymes in full kinetic inactivation assays, reducing the drug-drug interaction risk that typically complicates multi-agent oncology regimens at the formulation and clinical supply planning stage. Its approximately 1,400-fold selectivity for MTA-cooperative versus SAM-cooperative PRMT5 binding, combined with lack of brain penetrance, further supports a therapeutic window designed to accommodate rational combinations.

The Genentech collaboration is one of several parallel combination strategies IDEAYA is advancing for IDE892. A Phase 1 combination cohort with IDE397, IDEAYA's proprietary MAT2A inhibitor, is already underway in NSCLC and other solid tumors. IDEAYA also plans to initiate a Phase 1 cohort with Roche's RG6505 in MTAP-deleted, RAS-mutant PDAC in the second half of 2026, meaning supply chain and QA teams should anticipate concurrent investigational supply obligations across multiple sponsored and co-sponsored studies within a compressed timeline.

Each company retains independent commercial rights to its respective compound, both as monotherapy and in combination, preserving future licensing and commercialization optionality without creating shared IP encumbrances that could complicate technology transfer or manufacturing scale-up decisions downstream.

The joint governance structure's effectiveness in managing clinical supply deviations across two Phase 1 programs simultaneously will be a measurable operational checkpoint as both the GDC-7035 and RG6505 combination cohorts advance toward dose escalation.

Source: IDEAYA Biosciences newsroom via PR Newswire, 19 August 2026.